Cite

HARVARD Citation

    Michels, K. et al. (2023). Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering. Journal for immunotherapy of cancer. 11 (3), p. . [Online]. 
  
Back to record